Comparative evaluation of pharmaceutical products obtained in Mexico

Augmenting existing scientific data

Kelly L. Karlage, Stephen J. Franklin, Whe Christina Mufich, Kristen J. Goetz, Jennifer Vogel Sabelka, William L. Hoye, Paul B Myrdal

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Context: The accessibility of pharmacies in neighboring countries has facilitated the trend of acquiring medications outside of local borders. However, scientific data assessing the drug content and quality of these medications has not increased in a corresponding fashion. Objective: This study seeks to augment existing scientific data. Materials and methods: Seventeen products that were obtained from pharmacies in Mexico were evaluated for active ingredient content. The active pharmaceutical ingredients (API) assessed included amoxicillin, ampicillin, ciprofloxacin, levothyroxine, sildenafil citrate, sulfamethoxazole, trimethoprim, and warfarin. API content was analysed with high performance liquid chromatography assays and the resultant data interpreted by applying United States Pharmacopeia (USP) acceptability limits. Results: All of the samples analyzed for the two ciprofloxacin products and the two ampicillin products were found to be within the USP limits. Of the four different sulfamethoxazole/trimethoprim products tested, all were within USP limits for sulfamethoxazole, but contained 23 individual units which were outside of USP limits for trimethoprim. Several of the remaining products (amoxicillin, levothyroxine, sildenafil citrate, and warfarin) had individual units that fell outside of the USP limits, although only one of the levothyroxine products (1 out of 20 tablets tested) and both sildenafil citrate products (all of the units tested) contained units outside of ±25% label claim.

Original languageEnglish (US)
Pages (from-to)808-814
Number of pages7
JournalDrug Development and Industrial Pharmacy
Volume38
Issue number7
DOIs
StatePublished - 2012

Fingerprint

Pharmacopoeias
Mexico
Thyroxine
Amoxicillin
Sulfamethoxazole Drug Combination Trimethoprim
Warfarin
Ampicillin
Ciprofloxacin
Pharmaceutical Preparations
Pharmacies
Sulfamethoxazole
Trimethoprim
High performance liquid chromatography
Tablets
Labels
Assays
High Pressure Liquid Chromatography
Sildenafil Citrate

Keywords

  • Active pharmaceutical ingredient
  • Content analysis
  • Drug products
  • Quality control
  • Substandard medications

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Organic Chemistry
  • Medicine(all)

Cite this

Comparative evaluation of pharmaceutical products obtained in Mexico : Augmenting existing scientific data. / Karlage, Kelly L.; Franklin, Stephen J.; Mufich, Whe Christina; Goetz, Kristen J.; Sabelka, Jennifer Vogel; Hoye, William L.; Myrdal, Paul B.

In: Drug Development and Industrial Pharmacy, Vol. 38, No. 7, 2012, p. 808-814.

Research output: Contribution to journalArticle

Karlage, Kelly L. ; Franklin, Stephen J. ; Mufich, Whe Christina ; Goetz, Kristen J. ; Sabelka, Jennifer Vogel ; Hoye, William L. ; Myrdal, Paul B. / Comparative evaluation of pharmaceutical products obtained in Mexico : Augmenting existing scientific data. In: Drug Development and Industrial Pharmacy. 2012 ; Vol. 38, No. 7. pp. 808-814.
@article{bf736327cf4845b48264c15520507161,
title = "Comparative evaluation of pharmaceutical products obtained in Mexico: Augmenting existing scientific data",
abstract = "Context: The accessibility of pharmacies in neighboring countries has facilitated the trend of acquiring medications outside of local borders. However, scientific data assessing the drug content and quality of these medications has not increased in a corresponding fashion. Objective: This study seeks to augment existing scientific data. Materials and methods: Seventeen products that were obtained from pharmacies in Mexico were evaluated for active ingredient content. The active pharmaceutical ingredients (API) assessed included amoxicillin, ampicillin, ciprofloxacin, levothyroxine, sildenafil citrate, sulfamethoxazole, trimethoprim, and warfarin. API content was analysed with high performance liquid chromatography assays and the resultant data interpreted by applying United States Pharmacopeia (USP) acceptability limits. Results: All of the samples analyzed for the two ciprofloxacin products and the two ampicillin products were found to be within the USP limits. Of the four different sulfamethoxazole/trimethoprim products tested, all were within USP limits for sulfamethoxazole, but contained 23 individual units which were outside of USP limits for trimethoprim. Several of the remaining products (amoxicillin, levothyroxine, sildenafil citrate, and warfarin) had individual units that fell outside of the USP limits, although only one of the levothyroxine products (1 out of 20 tablets tested) and both sildenafil citrate products (all of the units tested) contained units outside of ±25{\%} label claim.",
keywords = "Active pharmaceutical ingredient, Content analysis, Drug products, Quality control, Substandard medications",
author = "Karlage, {Kelly L.} and Franklin, {Stephen J.} and Mufich, {Whe Christina} and Goetz, {Kristen J.} and Sabelka, {Jennifer Vogel} and Hoye, {William L.} and Myrdal, {Paul B}",
year = "2012",
doi = "10.3109/03639045.2011.628678",
language = "English (US)",
volume = "38",
pages = "808--814",
journal = "Drug Development and Industrial Pharmacy",
issn = "0363-9045",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Comparative evaluation of pharmaceutical products obtained in Mexico

T2 - Augmenting existing scientific data

AU - Karlage, Kelly L.

AU - Franklin, Stephen J.

AU - Mufich, Whe Christina

AU - Goetz, Kristen J.

AU - Sabelka, Jennifer Vogel

AU - Hoye, William L.

AU - Myrdal, Paul B

PY - 2012

Y1 - 2012

N2 - Context: The accessibility of pharmacies in neighboring countries has facilitated the trend of acquiring medications outside of local borders. However, scientific data assessing the drug content and quality of these medications has not increased in a corresponding fashion. Objective: This study seeks to augment existing scientific data. Materials and methods: Seventeen products that were obtained from pharmacies in Mexico were evaluated for active ingredient content. The active pharmaceutical ingredients (API) assessed included amoxicillin, ampicillin, ciprofloxacin, levothyroxine, sildenafil citrate, sulfamethoxazole, trimethoprim, and warfarin. API content was analysed with high performance liquid chromatography assays and the resultant data interpreted by applying United States Pharmacopeia (USP) acceptability limits. Results: All of the samples analyzed for the two ciprofloxacin products and the two ampicillin products were found to be within the USP limits. Of the four different sulfamethoxazole/trimethoprim products tested, all were within USP limits for sulfamethoxazole, but contained 23 individual units which were outside of USP limits for trimethoprim. Several of the remaining products (amoxicillin, levothyroxine, sildenafil citrate, and warfarin) had individual units that fell outside of the USP limits, although only one of the levothyroxine products (1 out of 20 tablets tested) and both sildenafil citrate products (all of the units tested) contained units outside of ±25% label claim.

AB - Context: The accessibility of pharmacies in neighboring countries has facilitated the trend of acquiring medications outside of local borders. However, scientific data assessing the drug content and quality of these medications has not increased in a corresponding fashion. Objective: This study seeks to augment existing scientific data. Materials and methods: Seventeen products that were obtained from pharmacies in Mexico were evaluated for active ingredient content. The active pharmaceutical ingredients (API) assessed included amoxicillin, ampicillin, ciprofloxacin, levothyroxine, sildenafil citrate, sulfamethoxazole, trimethoprim, and warfarin. API content was analysed with high performance liquid chromatography assays and the resultant data interpreted by applying United States Pharmacopeia (USP) acceptability limits. Results: All of the samples analyzed for the two ciprofloxacin products and the two ampicillin products were found to be within the USP limits. Of the four different sulfamethoxazole/trimethoprim products tested, all were within USP limits for sulfamethoxazole, but contained 23 individual units which were outside of USP limits for trimethoprim. Several of the remaining products (amoxicillin, levothyroxine, sildenafil citrate, and warfarin) had individual units that fell outside of the USP limits, although only one of the levothyroxine products (1 out of 20 tablets tested) and both sildenafil citrate products (all of the units tested) contained units outside of ±25% label claim.

KW - Active pharmaceutical ingredient

KW - Content analysis

KW - Drug products

KW - Quality control

KW - Substandard medications

UR - http://www.scopus.com/inward/record.url?scp=84861490525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861490525&partnerID=8YFLogxK

U2 - 10.3109/03639045.2011.628678

DO - 10.3109/03639045.2011.628678

M3 - Article

VL - 38

SP - 808

EP - 814

JO - Drug Development and Industrial Pharmacy

JF - Drug Development and Industrial Pharmacy

SN - 0363-9045

IS - 7

ER -